Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Oct 7, 2016 in Rheumatoid Arthritis | 0 comments

In a nutshell

This study compared the effectiveness of different biological drugs in patients with rheumatoid arthritis who have already been unresponsive to anti-tumor necrosis factor (TNF) treatment. The authors concluded that a non-TNF biological treatment was more effective at lowering disease activity than taking a second anti-TNF drug. 

Some background

There are many forms of treatment for rheumatoid arthritis (RA). Biological drugs are becoming a more commonly prescribed treatment option. There are many types of biological drugs with anti-tumor necrosis factor (TNF) drugs, such as adalimumab (Humira) or infliximab (Remicade), the most widely used. They work by blocking the activity of a protein called tumor necrosis factor. This protein is known to contribute to inflammation seen in RA.

If a patient does not respond to primary anti-TNF treatment, a second anti-TNF drug may be prescribed. Alternatively, a patient may be prescribed a completely different biological drug such as rituximab (Rituxan), tocilizumab (Actemra), or abatacept (Orencia). What kind of secondary treatment is most beneficial for patients unresponsive to primary anti-TNF therapy is still under investigation.

Methods & findings

269 RA patients with persistent disease activity were included in this study. All patients had previously received treatment with an anti-TNF drug and were not responding to treatment.

Patients were randomly assigned to receive either a second anti-TNF drug or a non TNF-targeted drug. The non TNF-targeted drugs were abatacept, tocilizumab, or rituximab. The study was carried out over 52 weeks. The authors looked at responsiveness of patients to their treatment after 24 weeks.

69% of patients receiving non-TNF drugs showed good or moderate response to their treatment. In contrast, 52% of those receiving a second anti-TNF drug showed the same response. 45% of patients in the non-TNF group showed low disease activity at 24 weeks. This was significantly greater compared to 28% with anti-TNF treatment. 

The bottom line

The authors concluded that a non-TNF drug was more effective at lowering disease activity than a second anti-TNF drug in patients unresponsive to primary anti-TNF therapy.

The fine print

Some of the authors are affiliated with the manufacturers drugs used in this study. 

Published By :

Journal of the American Medical Association (JAMA)

Date :

Sep 20, 2016

Original Title :

Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial.

click here to get personalized updates